<DOC>
	<DOCNO>NCT01890759</DOCNO>
	<brief_summary>The purpose study assess immunogenicity safety Menactra® vaccine give two-dose series infant toddler . Primary Objectives : - To assess seroprotection rate ( percentage subject serum bactericidal assay use human complement [ SBA-HC ] titer ≥ 1:8 ) 28 day second 2 dos Menactra® administer 3 6 month apart . Secondary Objectives : - To assess immune response meningococcal antigen ( serogroups A , C , Y , W-135 ) 28 day follow second vaccination Menactra® use SBA-HC SBA-BR titer . - To assess safety profile Menactra® vaccination .</brief_summary>
	<brief_title>Immunogenicity Safety Menactra® Vaccine Subjects Aged 9 23 Months India Russian Federation</brief_title>
	<detailed_description>Study participant receive 2 dos Menactra® vaccine 3 6 month apart monitor safety immunogenicity . The planned duration subject 's participation trial 118 215 day .</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female subject age 9 17 month day inclusion Informed consent form sign dated parent ( ) legally acceptable representative ( ) ( applicable ) Subject parent/legally acceptable representative ( applicable ) able attend schedule visit comply trial procedure . Participation 4 week precede inclusion plan participation present trial period another clinical trial investigate vaccine , drug , medical device , medical procedure . Receipt vaccine 4 week precede trial vaccination plan receipt vaccine 4 week follow trial vaccination , except : ( ) influenza vaccination , may receive least 2 week study vaccine . ( ii ) measles ( M ) measles , mumps , rubella ( MMR ) routine vaccination , administer concomitantly first dose study vaccine per routine immunization schedule ( iii ) subject enrolled Indian site : oral poliomyelitis vaccine ( OPV ) receive National Immunization Days ( NIDs ) supplementary immunization activity day ( SIADs ) Previous vaccination meningococcal disease either study vaccine another meningococcal vaccine Receipt immune globulin , blood bloodderived product past 3 month Known suspected congenital acquire immunodeficiency ; receipt immunosuppressive therapy , anticancer chemotherapy radiation therapy , within precede 6 month ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) History meningococcal disease , confirm either clinically , serologically , microbiologically At high risk , opinion Investigator , meningococcal disease trial Known suspect systemic hypersensitivity vaccine component , history lifethreatening reaction vaccine use trial vaccine contain substance Known thrombocytopenia , contraindicate intramuscular vaccination Bleeding disorder , receipt anticoagulant 3 week precede inclusion , contraindicate intramuscular vaccination In emergency setting , hospitalize involuntarily Chronic illness , opinion investigator , stage might interfere trial conduct completion For subject enrolled Indian site : Moderate severe acute illness/infection ( accord investigator judgment ) day vaccination febrile illness ( temperature ≥ 38.0°C ) . For subject enrol Russian site : Acute disease severity day vaccination febrile illness ( axillary temperature ≥ 37.0°C ) . A prospective subject include study condition resolve febrile event subside . Receipt oral injectable antibiotic therapy within 72 hour prior first blood draw Identified natural adopt child Investigator employee direct involvement propose study Personal history GuillainBarré Syndrome .</criteria>
	<gender>All</gender>
	<minimum_age>9 Months</minimum_age>
	<maximum_age>17 Months</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Meningitis</keyword>
	<keyword>Meningococcal Infection</keyword>
	<keyword>Menactra®</keyword>
</DOC>